Core Viewpoint - Zhaoyan New Drug has announced a significant increase in its 2025 annual performance forecast, with a minimum increase of 945% in net profit excluding non-recurring items, despite a projected decrease in revenue [1][2]. Group 1: Financial Performance - The company expects to achieve an operating income of approximately 1.573 billion to 1.738 billion yuan in 2025, representing a decrease of about 13.9% to 22.1% compared to 2024 [2]. - The projected net profit for 2025 is estimated to be between 233 million to 349 million yuan, an increase of approximately 214% to 371% year-on-year [2]. - The net profit excluding non-recurring items is expected to be between 246 million to 370 million yuan, reflecting an increase of approximately 945.2% to 1467.7% compared to 2024 [2]. Group 2: Asset Valuation and Pricing - The increase in net profit is attributed to the positive change in the fair market value of biological assets, contributing approximately 452 million to 499 million yuan to net profit [2]. - The biological assets primarily consist of experimental models used for non-clinical research, with a significant price increase expected in the second half of 2025 [3]. - The average procurement price for non-human primate experimental animals reached a high of 150,000 to 200,000 yuan per unit in the second half of 2022, but declined to 70,000 to 100,000 yuan per unit by the second half of 2024 [3]. Group 3: Shareholder Actions - Following the strong performance of the stock, the actual controller of Zhaoyan New Drug, Zhou Zhiwen, has initiated a share reduction plan, having already sold over 10 million shares for more than 370 million yuan [1][4]. - As of January 26, 2026, the closing price of Zhaoyan New Drug was 41.39 yuan, with a market capitalization of approximately 31.02 billion yuan [4]. - Zhou Zhiwen plans to reduce his holdings by up to 14.98 million shares, which is about 1.99873% of the total share capital [4].

国际医学公告，预计2025年度净利润亏损3.15亿元～2.95亿元，上年同期亏损2.54亿元。报告期内，公 司受市场波动、DRG支付政策改革等行业动态调整影响，营业收入同比下降。公司采取调整业务结 构，实施降本增效等措施并持续改善经营成效，第四季度亏损幅度收窄，但营业收入总规模尚未能覆盖 运营成本和期间费用。 ...

Core Viewpoint - Jimin Health (603222) expects a net loss of 210 million to 250 million yuan for 2025, which is an increase compared to the previous year's loss of 59.71 million yuan [1] Financial Performance - The company anticipates a non-recurring net loss of 205 million to 245 million yuan for 2025 [1] - The company has recognized an inventory impairment provision of approximately 37 million yuan for its pre-filled catheter flushing devices and safety syringes [1] Legal and Compliance Issues - Due to the case involving the forgery of company seals by He Qinghong and others, the company has confirmed related losses of approximately 38 million yuan [1] Asset Valuation - The performance of Ezhou Second Hospital is expected to decline in 2025, leading the company to recognize a goodwill impairment provision of approximately 20 million yuan [1] - After this provision, the cumulative impairment recognized will be approximately 136 million yuan, with a remaining book value of about 15.14 million yuan [1]

第二，持续巩固提升基础医疗服务和设施水平。发挥国家医学中心和区域医疗中心辐射带动作用， 加强三级医院帮扶二级医院、二级医院帮扶一级医院和基层机构，推动以人员为重点的资源下沉，同步 实施服务、技术、管理下沉基层。全面建立国家、省、市、县、乡五级巡回医疗制度，实现常态化巡回 医疗在资源薄弱县全覆盖。进一步推进全民健康数智化建设，推进基层医疗卫生机构与二三级医疗机构 电子病历、电子健康档案等互通共享，建立居民连续用药记录管理机制，推进居民电子健康档案应用安 全有序向个人开放，探索医学人工智能辅助诊疗基层应用，提高基层服务能力和水平条件。持续开展病 房改造提升、医疗设备更新等工作，提升基层医疗卫生机构设备设施及其数智化水平，改善看病就诊条 件和效果。 第三，持续提升基本公共卫生服务和基本医疗服务水平。优化基本公共卫生服务项目，充实内容， 量化频次。加强基层慢性病多病共防共管和医防融合。持续推进家庭医生签约服务高质量发展，不断提 高签约服务群众满意度。按程序动态调整医疗服务价格，完善不同层级医疗卫生机构差别化支付政策， 支付比例向基层医疗卫生机构明显倾斜，支持县域医共体持续完善薪酬分配政策。持续加强县级医疗机 构学科建 ...

Industry Investment Rating - The industry investment rating is "Outperform the Market" and is maintained [1] Core Views - The report highlights the ongoing decline in the national population and birth rates, with a significant increase in the elderly population, which is expected to drive demand for home medical devices and supplies [5][21] - The report emphasizes the long-term positive trend in the innovative drug sector, supported by the strength of China's innovative drug companies in global competition [7] - The medical device sector is showing signs of improvement, with major companies reporting better performance in Q3, indicating a potential recovery in the industry [9] Summary by Relevant Sections Industry Overview - As of January 26, 2026, the closing index stands at 8623.36, with a 52-week high of 9323.49 and a low of 6876.88 [1] Recent Market Performance - During the week of January 19-23, 2026, the A-share pharmaceutical sector fell by 0.39%, outperforming the CSI 300 index by 0.23 percentage points but underperforming the ChiNext index by 0.05 percentage points [6][24] - The medical device sector is expected to attract more investment as the pressure from centralized procurement diminishes [9][30] Population and Demographics - By the end of 2025, the total population of China was 1,404.89 million, with a natural population growth rate of -2.41% [15] - The elderly population (aged 65 and above) reached 22,365 million, accounting for 15.9% of the total population, indicating a trend towards an aging society [18][20] Investment Recommendations - The report suggests focusing on companies in the elderly care medical sector, such as Yuyue Medical, Kefu Medical, and Loxin Medical, due to the anticipated increase in demand for home medical devices [5][22] - In the innovative drug sector, companies like Innovent Biologics and Kintor Pharmaceutical are highlighted as beneficiaries of the growing global participation of Chinese innovative drug firms [7][27] - For the medical device sector, companies such as Mindray and Hunan Aohua are recommended due to their improving performance and market position [9][30] Future Outlook - The report anticipates a recovery in the medical device sector as procurement policies become more reasonable and the pressure from centralized procurement decreases [30] - The innovative drug sector is expected to continue its upward trajectory, with more innovative projects anticipated in 2026 [26][28]

2025年，乐城先行区接待医疗旅游人数86.53万人次，同比增长109.18% 博鳌乐城缘何"圈粉"海内外? ①博鳌乐城"永不落幕"国际创新药械展迎来大批国内外游客。 在这片繁忙而有序的"医疗特区"里，不少特许药械正享受着"零关税"政策的红利，从入库到配送，全流 程高效运转，随时准备为国内患者带来康复的希望。 "'零关税'政策对于我们这些在乐城先行区内注册的医疗机构来说可谓是'锦上添花'，不仅可以减轻患者 用药用械成本，也为我们企业资金周转提供了很大的便利。"海南博鳌超级医院相关负责人冯家龙的话语，道 出了众多入驻机构的心声。 翻开博鳌乐城国际医疗旅游先行区(以下简称乐城先行区)一年来的发展画卷，起笔有势，落笔生辉。 这一年，乐城先行区交出了一份亮眼的成绩单：医疗旅游人次同比增长109.2%，特许药械使用人次同比 增长139.9%，全年引进国际创新药械和特殊食品首次突破100种，其中创新药械89种……这些数字背后，不 仅是量的积累，更是质的飞跃。 这一年，乐城先行区以制度集成创新为笔，以开放合作共赢为墨，在万泉河畔书写了医疗健康事业发展 的崭新篇章。从特许药械引进数量的井喷式增长，到生物医学新技术临床转化的破 ...

▶ 尾号限行 3和8 ▶ 北京今年经济社会发展主要预期目标发布！一图速览 ▶ 北京市计划报告：七大任务聚焦发展 ▶ 今日天气 白天多云转晴，偏北风二三级（阵风五级左右），最高气温5℃；夜间晴转多云，偏北风二三级，最低 气温-7℃。 今天偏北阵风较大，风寒效应明显。 2026年北京市将加快超大城市发展方式转型，提升城市精细化治理水平。抓好507栋危旧简易楼排险工 作，改造完工老旧小区300个以上，实施老楼加装电梯800台以上，深入开展第三轮回天行动，持续推进 城中村改造。 ▶ 轨道交通22号线红庙至平谷段今年基本具备开通条件 北京将促进通勤圈一体发展，轨道交通22号线红庙至平谷段基本具备开通条件，做好跨界交通接驳，优 化提升应寺、永乐等进京检查站。 ▶ 北京市居民人均预期寿命达83.9岁 北京"一老一小"服务全面提升，人均预期寿命从2020年的82.4岁提升至83.9岁，民生改善更加可感可 及。 北京今年实施的七大任务聚焦"发展"二字：内需主导发展、创新驱动发展、改革推动发展、规划引领发 展、城市内涵发展、人民共享发展、安全保障发展。 ▶ 今年北京将新建绿道1000公里！四环路将变身"月季花环" 2026年北京 ...

Core Viewpoint - The article highlights the advancements in healthcare infrastructure and services in Qinghai Province, focusing on the establishment of regional medical centers and improvements in medical insurance funding [2][3]. Group 1: Goals - The aim is to establish a long-term mechanism for medical insurance coverage, optimize the funding structure for urban and rural residents' medical insurance, and increase the fiscal subsidy standard [2]. - The plan includes the construction of national regional medical centers and provincial-level regional medical centers in specific areas [2]. Group 2: Progress - The fiscal subsidy standard for urban and rural residents' medical insurance has been increased by 20 yuan, reaching 700 yuan, with a per capita funding standard of 1,100 yuan, aligning with national standards [3]. - The national regional medical center has officially commenced operations, with provincial-level centers in Haidong City, Hainan Prefecture, and Yushu Prefecture completed and operational [3]. - A pilot program for "no companion" wards has been initiated in 10 medical institutions, covering 57 high-demand nursing areas, with plans to expand to 16 institutions and 221 wards [3]. - All 59 second and third-level public general hospitals, 14 public traditional Chinese medicine hospitals, and 52 maternal and child health institutions at the county level and above now provide pediatric services [3]. - The number of mutual recognition projects for inspection results between medical institutions has increased from 54 to 243, with 27 institutions included in the "8 provincial regional inspection result mutual recognition units," an increase of 13 from 2024 [3]. Group 3: Reactions - The presence of nationally recognized medical experts, such as Professor Li Weixin from Xi'an Jiaotong University First Affiliated Hospital, has attracted many patients, demonstrating the effectiveness of local healthcare services [4]. - The establishment of the first national regional medical center in Qinghai Province aims to alleviate the burden of seeking medical care from distant locations and ensure that local populations have access to high-quality medical services [4].

Core Insights - The article highlights the significant progress made by Yushu Tibetan Autonomous Prefecture during the 14th Five-Year Plan period, focusing on various sectors including culture, tourism, agriculture, and healthcare [1][9]. Group 1: Cultural and Tourism Development - Yushu has positioned itself as a preferred international ecological tourism destination, enhancing its cultural tourism service system and integrating local cuisine and hospitality [2][3]. - The region has received 6.4185 million tourists, generating a total tourism expenditure of 4.175 billion yuan, which has created nearly 20,000 jobs [3]. - The establishment of a digital archive for intangible cultural heritage has led to the systematic protection of 834 representative projects, showcasing the region's cultural richness [3]. Group 2: Agricultural Advancements - Yushu's agricultural sector is anchored by yak and Tibetan sheep industries, creating a comprehensive supply chain from breeding to sales [4]. - The region boasts 120 million acres of organic certified grasslands and five geographical indication products, enhancing the quality and safety of agricultural products [4]. - The yak wool sales reached 50 tons annually, supported by modern processing facilities and established quality standards [3][4]. Group 3: Ecological Improvements - Yushu has seen a significant increase in flagship species, with the black-necked crane population rising from 22 to over 220, and the Tibetan antelope population increasing from under 20,000 to 70,000 [5][6]. - The region's water quality has improved, with 99.6% of surface water meeting excellent standards, and air quality showing 99.97% of days classified as good [6]. - Yushu has been recognized as a national ecological civilization demonstration zone, with ongoing initiatives for waste management and ecological protection [6]. Group 4: Healthcare Enhancements - The establishment of the provincial-level medical center in Yushu has alleviated healthcare access issues, with a 28.53% increase in advanced surgical procedures [8]. - A comprehensive telemedicine system has been implemented, allowing residents to access expert medical services remotely [8]. - The region has focused on improving healthcare quality and expanding resources, contributing to the overall well-being of the population [7][8]. Group 5: Infrastructure and Transportation - The completion of the G0613 highway segment has improved connectivity, facilitating travel and enhancing the transportation network [8]. - The integration of transportation infrastructure supports the overall development of the region, contributing to economic growth and accessibility [8]. Group 6: Future Outlook - Yushu aims to continue its development trajectory towards 2035, with goals for significant economic growth, increased per capita GDP, and improved living standards for residents [9].

"不少医院门诊高峰时段，在挂号机前、候诊区、诊室门口及药房窗口排长队大都是两类人群，一类是 需要检查诊断、调整用药，还有一类是拿着药盒或既往处方仅来续方开药。两类人群不同需求但是要走 同一条流程、占同一批号源、挤同一套窗口，同一个诊室门口，有人拿着检查单等复诊评估，有人只需 要续方。"沈腾说，不少稳定慢病患者只是按既定方案续方，但仍要重复经历"挂号—候诊—开方—缴费 —取药"，特别是对腿脚不便的老人来说，续一次药就像完成一次"半日工程"。 文/本报记者 董鑫 他建议，医院建立"续方快线"，把续方人群从普通门诊中分出来，优化续方手续，推行"一次告知、一 张清单、一次办结"，可以设立续方门诊或者续方窗口、专区等，专门服务稳定慢病续方、常规复核、 既往方案延续的人群。 来自社会科学界的北京市政协委员、北京市帅和律师事务所主任沈腾关注就医便利话题。他建议，医院 建立"续方快线"，让普通门诊的续方人群与看病人员分流出来，同时优化续方手续，推行"一次告知、 一张清单、一次办结"。 同时，探索"社区复查+续方""线上评估+线下取药"等组合，并用"保供清单+缺药响应"等方式提升基层 医疗机构常用药的可及性与稳定性，让续方从" ...